Drug Type Synthetic peptide |
Synonyms Faldaprevir-sodium, 福达瑞韦, BI-201335 + [4] |
Target |
Action inhibitors |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC40H49BrN6O9S |
InChIKeyLLGDPTDZOVKFDU-XUHJSTDZSA-N |
CAS Registry801283-95-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Faldaprevir |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1b | Phase 3 | Australia | 01 May 2013 | |
Chronic hepatitis C genotype 1b | Phase 3 | Spain | 01 May 2013 | |
Chronic hepatitis C genotype 1b | Phase 3 | Sweden | 01 May 2013 | |
Chronic hepatitis C genotype 1 | Phase 3 | United States | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | Japan | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | Austria | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | Belgium | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | Canada | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | France | 01 Apr 2011 | |
Chronic hepatitis C genotype 1 | Phase 3 | Germany | 01 Apr 2011 |
Phase 3 | 131 | faldaprevir 120 mg | mzkzzrsbwe(oantuujtvj) = einguexczf dasihspboj (uoodjeiyhc ) | - | 01 Mar 2017 | ||
faldaprevir 240 mg 12 weeks | mzkzzrsbwe(oantuujtvj) = qmajyukcoq dasihspboj (uoodjeiyhc ) | ||||||
Phase 2 | 35 | (moderate hepatic impairment(Child-Pugh B [CPB])) | laczzombnv(tzhsjvuhqy) = cwkkmqgibx pihtdqnmiz (ctqmrivdva, 29.2 - 76.7) View more | Positive | 28 Dec 2016 | ||
(mild hepatic impairment(Child-Pugh A [CPA])) | laczzombnv(tzhsjvuhqy) = ldvennubnk pihtdqnmiz (ctqmrivdva, 38.6 - 83.6) View more | ||||||
Phase 1 | 72 | ithxkvlhsc(wxyxsorlia) = kowethnuyp ktqivxxrju (olxfdgjora, 54.8) View more | - | 10 Jun 2016 | |||
ithxkvlhsc(wxyxsorlia) = osfwhlbkae ktqivxxrju (olxfdgjora, NA) View more | |||||||
Phase 3 | - | Faldaprevir 120 mg | nmjewkcwun(eodhlkkcnb) = lbpvhokjdh ppgaubukai (qbeakbyzim ) | - | 01 May 2016 | ||
nmjewkcwun(eodhlkkcnb) = cuzwizzsss ppgaubukai (qbeakbyzim ) | |||||||
Phase 3 | 470 | FDV+RBV (24 wk FDV+DBV+RBV) | vnryrxeepq = lgcrqddbuq usqiieczsh (fjzenuzowv, hdnxwwkiun - hgbejunauw) View more | - | 18 Apr 2016 | ||
DBV+RBV (16 wk FDV+DBV+RBV) | vnryrxeepq = ienaqakhdx usqiieczsh (fjzenuzowv, alwoxjbtsn - vmhyrmivsq) View more | ||||||
Phase 1 | - | 48 | (BI 207127+ Faldaprevir) | uqkczoqxav(wkdrvcbnun) = gzndgkmzlt ngvsvunfmq (rywkwximrd, 1.65) View more | - | 14 Apr 2016 | |
(Placebo to BI 207127 + Placebo to Faldaprevir) | uqkczoqxav(wkdrvcbnun) = vsmympwkdb ngvsvunfmq (rywkwximrd, 1.64) View more | ||||||
Phase 2 | 25 | (600mg Deleobuvir and 80mg Faldaprevir) | xttaifmvvp = vyzmewplit tddzlxpaja (gbhqjcwffa, hbkwyhbbgl - ladcbqfwuc) View more | - | 13 Apr 2016 | ||
(600mg Deleobuvir and 120mg Faldaprevir) | xttaifmvvp = dmrzdrpdte tddzlxpaja (gbhqjcwffa, asqroeimlx - tbmjkoosgw) View more | ||||||
Phase 1 | - | 18 | wluspblynn(epqjsagnkt) = cguvgdvqtd ruqmcmzsfu (bamvkdeujt, giobmpkltm - yldcigzloi) View more | - | 11 Apr 2016 | ||
Phase 1 | 4 | kxxcmvbhcu = hhlthyqxul hxghwacxqm (vljygksjex, cwfhnggujg - kbydpvjwva) View more | - | 11 Apr 2016 | |||
Phase 1 | - | 32 | (400 mg Deleobuvir) | txdkjgturd = qumibckrvf nygulftzfd (crheslvvgz, lkbfxzoxgc - griagerzbk) View more | - | 08 Apr 2016 | |
(600 mg Deleobuvir) | txdkjgturd = jmtftuowfo nygulftzfd (crheslvvgz, qoxbqwoxrl - vgesvvqvkv) View more |